2012
Contribution of Endogenous Bradykinin to Fibrinolysis, Inflammation, and Blood Product Transfusion Following Cardiac Surgery: A Randomized Clinical Trial
Balaguer JM, Yu C, Byrne JG, Ball SK, Petracek MR, Brown NJ, Pretorius M. Contribution of Endogenous Bradykinin to Fibrinolysis, Inflammation, and Blood Product Transfusion Following Cardiac Surgery: A Randomized Clinical Trial. Clinical Pharmacology & Therapeutics 2012, 93: 326-334. PMID: 23361105, PMCID: PMC4031681, DOI: 10.1038/clpt.2012.249.Peer-Reviewed Original ResearchConceptsBradykinin B2 receptor antagonismB2 receptor antagonismCardiopulmonary bypassEndogenous bradykininTissue-type plasminogen activatorHoe 140Receptor antagonismBradykinin B2 receptor antagonistSubsequent transfusion requirementsBlood product transfusionProportion of patientsB2 receptor antagonistD-dimer concentrationD-dimer formationEACA treatmentTransfusion requirementsPostoperative bleedingProduct transfusionBlood lossCardiac surgeryInflammatory cytokinesReceptor antagonistClinical trialsFibrinolytic capacityInflammatory response
2009
Endogenous Bradykinin Contributes to Increased Plasminogen Activator Inhibitor 1 Antigen following Hemodialysis
Marney AM, Ma J, Luther JM, Ikizler TA, Brown NJ. Endogenous Bradykinin Contributes to Increased Plasminogen Activator Inhibitor 1 Antigen following Hemodialysis. Journal Of The American Society Of Nephrology 2009, 20: 2246-2252. PMID: 19628666, PMCID: PMC2754101, DOI: 10.1681/asn.2009050505.Peer-Reviewed Original ResearchConceptsPlasminogen activator inhibitor-1 antigenHoe 140Endogenous bradykininHemodialysis patientsMCP-1Receptor blocker HOE-140Placebo-controlled crossover studyOxidative stressChronic hemodialysis patientsMean arterial pressureCoronary artery diseaseKallikrein-kinin systemBradykinin receptor antagonismHeart rate responsePAI-1 antigenTissue plasminogen activatorEffect of dialysisEnd of dialysisProduction of bradykininInhibits platelet aggregationCardiovascular eventsHemodialysis populationArterial pressureArtery diseaseEndothelial release
2006
Bradykinin B2 Receptor Does Not Contribute to Blood Pressure Lowering during AT1 Receptor Blockade
LeFebvre J, Shintani A, Gebretsadik T, Petro JR, Murphey LJ, Brown NJ. Bradykinin B2 Receptor Does Not Contribute to Blood Pressure Lowering during AT1 Receptor Blockade. Journal Of Pharmacology And Experimental Therapeutics 2006, 320: 1261-1267. PMID: 17182977, DOI: 10.1124/jpet.106.117259.Peer-Reviewed Original ResearchConceptsPlasma renin activityHoe 140Endogenous bradykininReceptor blockadeBaseline plasma renin activityBlood pressure-lowering effectAT1 receptor blockadeSalt-depleted subjectsBlood pressure loweringBlood pressure responseEffect of angiotensinPressure-lowering effectAngiotensin I/Heart rate responseReceptor-independent mechanismD-Arg-ArgBradykinin B2 receptorPRA responseRenin activityChronic treatmentPlasma cGMPPressure loweringB2 receptorsEndocrine responsesHeart rate
2005
A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine‐related hypotension after cardiopulmonary bypass
Pretorius M, Scholl FG, McFarlane JA, Murphey LJ, Brown NJ. A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine‐related hypotension after cardiopulmonary bypass. Clinical Pharmacology & Therapeutics 2005, 78: 477-485. PMID: 16321614, DOI: 10.1016/j.clpt.2005.08.010.Peer-Reviewed Original ResearchConceptsMean arterial pressureSaline solution groupT-PA activityAdministration of protamineCardiopulmonary bypassProtamine administrationHoe 140Receptor antagonismBradykinin concentrationsSolution groupTissue-type plasminogen activator releaseACE inhibitor-treated patientsBradykinin B2 receptor antagonismReceptor antagonist HOE 140Angiotensin-converting enzyme inhibitorB2 receptor antagonismInhibitor-treated patientsElective cardiac surgeryAdult male patientsBradykinin receptor antagonismDegradation of bradykininPlasminogen activator releaseSaline solutionProtamine infusionArterial pressure
2003
Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin
Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin. Circulation 2003, 107: 579-585. PMID: 12566370, DOI: 10.1161/01.cir.0000046268.59922.a4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAngiotensin-Converting Enzyme InhibitorsBlood Flow VelocityBradykininBradykinin Receptor AntagonistsDose-Response Relationship, DrugEnalaprilatEndothelium, VascularFemaleFibrinolysisForearmHumansInfusions, Intra-ArterialMaleMethacholine ChlorideMuscarinic AgonistsRegional Blood FlowSmokingTissue Plasminogen ActivatorVascular ResistanceConceptsForearm blood flowNet t-PA releaseT-PA releaseEndothelial t-PA releaseHoe 140T-PA responseEndogenous bradykininACE inhibitionExogenous bradykininTissue-type plasminogen activator releaseReceptor antagonist HOE 140Angiotensin-Converting Enzyme InhibitionBradykinin receptor antagonist HOE 140Effects of enalaprilatIntra-arterial enalaprilatIntra-arterial infusionPlasminogen activator releaseEnzyme inhibitionFBF responseVascular resistanceBlood flowActivator releaseEnalaprilatBradykininMethacholine
2000
Endogenous bradykinin and the renin and pressor responses to furosemide in humans.
Murphey LJ, Kumar S, Brown NJ. Endogenous bradykinin and the renin and pressor responses to furosemide in humans. Journal Of Pharmacology And Experimental Therapeutics 2000, 295: 644-8. PMID: 11046100.Peer-Reviewed Original ResearchConceptsPlasma renin activityMean arterial pressureHoe 140Renin responseEndogenous bradykininRenin activityArterial pressureHeart rateBasal plasma renin activityRenin-angiotensin systemAngiotensin I/Blood pressure regulationCrossover design studyAcute furosemide treatmentRenin regulationSpecific bradykininDiuretic responseFurosemide administrationFurosemide treatmentACE inhibitionReceptor antagonistPressure regulationBradykininFurosemideHumansBradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B2 Receptor–Dependent, NO Synthase–Independent, and Cyclooxygenase-Independent Pathway
Brown N, Gainer J, Murphey L, Vaughan D. Bradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B2 Receptor–Dependent, NO Synthase–Independent, and Cyclooxygenase-Independent Pathway. Circulation 2000, 102: 2190-2196. PMID: 11056091, DOI: 10.1161/01.cir.102.18.2190.Peer-Reviewed Original ResearchMeSH Keywords6-Ketoprostaglandin F1 alphaAcetylcholineAdrenergic beta-AntagonistsAdultBradykininBradykinin Receptor AntagonistsCyclooxygenase InhibitorsEndothelium, VascularFemaleForearmHumansIndomethacinInfusions, Intra-ArterialMaleNitric Oxide SynthaseNitroprussideOmega-N-MethylargininePlethysmographyReceptor, Bradykinin B2Regional Blood FlowTissue Plasminogen ActivatorVasodilationVasodilator AgentsConceptsTissue plasminogen activator releaseVasodilator responseL-NMMAPlasminogen activator releaseCyclooxygenase-independent pathwayTPA releaseActivator releaseBasal forearm blood flowReceptor antagonist HOE 140NO synthase inhibitor LHuman endotheliumHuman forearm vasculatureForearm blood flowEffect of indomethacinIntra-arterial bradykininReceptor-dependent effectsCyclooxygenase inhibitor indomethacinMonomethyl-L-arginineForearm vasodilationEndothelial effectsIndomethacin administrationForearm vasculatureHoe 140Receptor antagonismUrinary excretion